Juan Garcia, MD
Pulmonary Disease · Live Oak, TXNPI 1104856400
Payments from drug & device makers
Across 102 payments — averaging $47.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$3K
- GSK$611
- Inspire Medical Systems, Inc.$382
- AstraZeneca$201
- Inari Medical, Inc.$140
- Amgen$118
- plus $705 from 16 others
What the payments were for
- Consulting fees$2,53552%
- Food & beverage$2,34148%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 6 | $2,722 |
| GSK | 35 | $611 |
| Inspire Medical Systems, Inc. | 20 | $382 |
| AstraZeneca | 11 | $201 |
| Inari Medical, Inc. | 1 | $140 |
| Amgen | 1 | $118 |
| Pulmonx Corporation | 1 | $116 |
| Boehringer Ingelheim | 5 | $105 |
| Tactile Systems Technology Inc | 3 | $95 |
| ANI Pharmaceuticals, Inc. | 2 | $55 |
| AbbVie | 3 | $45 |
| Johnson & Johnson | 1 | $44 |
| United Therapeutics Corporation | 3 | $43 |
| Advanced Respiratory, Inc | 1 | $38 |
| Baxter Healthcare | 2 | $31 |
| Sanofi | 1 | $26 |
| Mylan Specialty L.p. | 1 | $21 |
| Vapotherm Inc | 1 | $20 |
| Itamar Medical Inc | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Merck | 1 | $15 |
| Electromed, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$2,649
- UPTRAVI$2,649
- FLOWTRIEVER CATHETER, S$140
- CT THROMBECTOMY SYSTEM KIT$140
- NUCALA$125
- Blincyto$118
- CHARTIS CATHETER$116
- ZEPHYR DELIVERY CATHETER$116
- ZEPHYR ENDOBRONCHIAL VALVE$116
- PULMONX CHARTIS TABLET CONSOLE$116
How this compares
$4,878 in reported general payments places this provider in the 55th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 275 | $304,583 |
| OpsumitMacitentan | 23 | $289,021 |
| Breo ElliptaFluticasone/Vilanterol | 151 | $83,720 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $63,634 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 52 | $45,486 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $45,469 |
| Dupixent SyringeDupilumab | 11 | $41,835 |
| Spiriva RespimatTiotropium Bromide | 38 | $33,089 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $18,597 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $10,031 |
| Wixela InhubFluticasone Propion/Salmeterol | 42 | $9,204 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $6,483 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 219 | $5,292 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $4,481 |
| Varenicline Tartrate | 15 | $4,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $611 | $452,370522 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $2,722 | $289,02123 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $105 | $78,57590 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $201 | $73,66596 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Live Oak
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.